Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 215(2020) vom: 15. Juni, Seite 108451
Auteur principal: Takatani, Ayuko (Auteur)
Autres auteurs: Koga, Tomohiro, Fujita, Yuya, Fukui, Shoichi, Endo, Yushiro, Shimizu, Toshimasa, Kawakami, Atsushi
Format: Article en ligne
Langue:English
Publié: 2020
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Case Reports Letter Research Support, Non-U.S. Gov't Anti-MDA5 antibody Dermatomyositis IL-15 Interstitial lung disease Tofacitinib Autoantibodies Piperidines plus... Protein Kinase Inhibitors Pyrimidines tofacitinib 87LA6FU830 IFIH1 protein, human EC 3.6.1.- Interferon-Induced Helicase, IFIH1 EC 3.6.4.13